-

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market

VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations representative.

Conference Call:

Date: September 9, 2021
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: 1-877-407-3982
International dial-in number: 1-201-493-6780
Conference ID: 13722893
Webcast: http://public.viavid.com/index.php?id=146463

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

Contacts

Investors:
LifeSci Advisors
John Mullaly
Email: jmullaly@lifesciadvisors.com

More News From ImmunoPrecise Antibodies Ltd.

MindWalk Announces Results of 2026 Annual General Meeting of Shareholders

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ: HYFT), a Bio-Native AI company, today announced the voting results of its 2026 Annual General Meeting of Shareholders held on November 17, 2026. A total of 18,619,753 common shares were represented by proxy at the meeting, representing 39.13% of the 47,574,512 common shares issued and outstanding as of the October 13, 2026 record date. Shareholders elected Dr. Jennifer L. Bath, Jon Lieber and Kim Remi...

MindWalk Closes US$30 Million Senior Unsecured Revolving Credit Facility

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has entered into a definitive senior unsecured revolving credit agreement with Sanabil Cayman providing a committed revolving credit facility of up to US$30 million. The agreement, dated November 16, 2026, implements the binding term sheet announced on September 14, 2026. The facility is undrawn, MindWalk is under no obligation to borrow, and no fee accrues on th...

MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (“Teva Australia”) to deploy ReefIQ™, MindWalk’s HYFT®-powered biological context layer with specified LensAI™ analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and ac...
Back to Newsroom